Kiniksa slims focus to cardiovascular diseases

Cardiovascular diseases specialist Kiniksa Pharmaceuticals International (Nasdaq: KNSA) has announced updates to its pipeline alongside fourth quarter and full year 2024 financial results.

 The UK firm already has an on-market therapy in the shape of Arcalyst (rilonacept), the first and only US Food and Drug Administration (FDA)-approved therapy for recurrent pericarditis, which brought in revenue of $122.5 million and $417 million for the fourth quarter and full year of 2024, respectively. The latter represents a rise of 79%. 

Arcalyst, which was discovered by US biotech major Regeneron Pharmaceuticals (Nasdaq: REGN), has also won approvals for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, and the maintenance of remission of deficiency of interleukin-1 receptor antagonist. For 2025, net product revenue for the drug is expected to be between $560 million and $580 million.